Clinical Trial Finder

The DMD Hub’s Clinical Trial Finder brings together trustworthy and reliable information on all existing and upcoming trials for Duchenne muscular dystrophy in the UK.

Our Clinical Trial Finder has been designed for patients and caregivers, to be as accessible and comprehensive as possible. Every trial has information on outcome measures, inclusion criteria and an easy to understand lay summary. You can use search filters to find trials that are relevant to you and download a fact sheet for each trial. The information on each trial has been sourced directly from industry and hospitals and is verified by Duchenne UK and the DMD Hub management team.

Please note that the DMD Hub is not responsible for the direct recruitment of patients to trials. Although we work closely with sites to ensure the recruitment status for every trial is accurate and up to date, there may be a delay in updating the Clinical Trial Finder while the patient screening process takes place.

We recommend that UK patients/parent and caregivers register with the Central Recruitment Pilot Project, which will enable trial sites to contact you directly if you are eligible for a study. 

The DMD Hub is not promoting any particular trial or therapy.  You should always consult your neuromuscular consultant before joining a trial. 

Sign up to the DMD Hub mailing list to be notified of new clinical trials and research studies and DMD Hub news.

Please remember that this information relies on the sponsors and trial sites keeping the DMD Hub updated with accurate information.

Location Trial Status:

= Fully recruited

= Recruiting

= Not yet recruiting

= Enrolling by invitation


Showing all 53 trials

DMD Hub logo

Italfarmaco - ULYSSES

Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy (ULYSSES)

Hub Summary

The main objective of this study is to demonstrate the efficacy of givinostat in reducing muscle decline in non-ambulant patients aged 9-17 with Duchenne Muscular Dystrophy.  Additional objectives are the evaluation of safety, tolerability of the drug and further exploration of efficacy of givinostat in non-ambulant DMD population.

Study Number: NCT05933057

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Italfarmaco
Age
9-17
Mutation Specific
All treatment types
Muscle Biopsy
Ambulation
Non-ambulant
DMD Hub logo

DMDhome

Decentralised study for validation of DMDhome, a platform for video capture and computer vision analysis of digital endpoints of upper/lower limb function relevant to the transfer phase in Duchenne muscular dystrophy (DMD).

Hub Summary

This decentralised study aims to evaluate whether new video-based electronic clinical outcome assessments (eCOAs) captured with the Atom5TM platform DMDhome are able to detect disease progression from the late ambulatory to transfer stage and early non-ambulatory stage, compared with standard validated clinical assessments.

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Aparito
Age
8 and above
Mutation Specific
All treatment types
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

BIND 2

Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5 and WP6) Part 2: a Neurobehavioural and MRI Study

Hub Summary

The objective of this study is to understand the relationship between DMD and BMD brain comorbidities, and the location of the gene mutation which causes the disease.

The investigators will recruit both patients who have completed a related online study (ClinicalTrials.gov Identifier NCT04583917) and patients directly recruited from participating clinics or research settings. These patients will undergo a structured cognitive and neurobehavioural assessment. A subgroup of patients assessed in the research setting will be invited to also attend a second visit involving a magnetic resonance imaging (MRI) scan of the brain.

The investigators aim to recruit 80 participants in the UK and the number of participants in the remaining countries will be 190 patients.

Study Number: NCT04668716

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Age
5-17
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Genethon- Microdystrophin Gene Therapy (GNT-016-MYDF)

GNT-016-MYDF: A phase I/II/III study with a dose determination part followed by an efficacy and safety evaluation of selected dose part and then by a long-term follow-up part in ambulant boys aged 6 to 10 years with DMD

Hub Summary

GNT0004 is a recombinant adenovirus-associated viral (AAV) vector gene therapy, composed of an AAV8 serotype capsid containing a sequence-optimised gene for a human microdystrophin.

Duchenne muscular dystrophy (DMD) is a neuromuscular disorder caused by dystrophin gene mutations leading to absence (almost absence) of functional dystrophin, a key protein that prevents muscle cell damage during physiological contractions. Conceptually, adding a functional copy of the gene to muscle cells would, in principle, treat the underlying cause of the disease. However, there are two main obstacles to overcome to achieve this. First, a vehicle (vector) is needed to transport the functioning gene to target muscle cells. AAV capsids are frequently used as the vehicle to transport genes in other gene therapy products. The specific type of AAV capsid in GNT0004 is called AAV8. The second obstacle to overcome is the size of the dystrophin gene. It is one of the largest genes in our bodies and because it is so large it cannot fit inside the AAV capsid. To address this obstacle, the Genethon research group has developed a miniaturized but functional version of dystrophin (Microdystrophin).

The principle of GNT0004 is to deliver an optimized microdystrophin protein to target tissues (heart and skeletal muscles) in DMD subjects. It is expected to significantly delay or slow down the progression of the disease in humans in a similar manner to how it has shown to be able to do this in animal models with the disease.

In order to help GNT0004 reach muscles throughout the body, GNT0004 will be given as a one-time intravenous (IV) infusion.

Study Number: EUDRACT N° 2020-002093-27

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Genethon
Age
6 to 10 years
Mutation Specific
Mutation specific therapies, Exclude mutations affecting exons 1-17 inclusive
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Antisense - ATL1102

A Multicentre, Randomised, Double-blind, Placebo-controlled and Open Label Extension Study to Assess the Efficacy, Safety, and Pharmacokinetic Profile of ATL1102 in Non-ambulatory Participants With Duchenne Muscular Dystrophy

Hub Summary

This Phase IIb study is a two part, multicenter study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ATL1102 in non-ambulant boys with Duchenne Muscular Dystrophy aged 10 to 17 years old. The study includes a randomised, double-blind, placebo-controlled treatment period (Part A), followed by an open labelled treatment period (Part B).

Study Number: NCT05938023

Learn More
Overall Trial Status
Recruiting
Trial Sponsor
Antisense Therapeutics Limited
Age
10 - 17
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Non-ambulant
DMD Hub logo

Dyne Therapeutics - DYNE-251

Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics Study of DYNE-251 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Hub Summary

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy, aged 4 to 16 years, Amenable to Exon 51 Skipping.

Study Number: NCT05524883

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Dyne Therapeutics, Inc
Age
4 to 16 years
Mutation Specific
Mutation specific therapies, 51 Skip-amenable only
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

NS Pharma - RACER53-X

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Hub Summary

This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.

The dystrophin gene has 79 pieces called exons. These link together to form a code which instructs the body to make dystrophin. If there is a fault, as in DMD, the sequence is broken and the code cannot be read. Exon skipping drugs complete the sequence and leads to a shortened dystrophin being produced that still contains the important pieces of this molecule.

Study Number: NCT04768062

Learn More
Overall Trial Status
Enrolling by invitation
Trial Sponsor
NS Pharma, Inc.
Age
5-8
Mutation Specific
Mutation specific therapies, Exon 53
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Hydrotherapy in DMD

Hydrotherapy for health in boys and adolescents with Duchenne muscular dystrophy

Hub Summary

Exercise is very important for young people to help keep them healthy. It could be as important for children and young people who have a muscle disease, like Duchenne muscular dystrophy (DMD). Hydrotherapy is a form of exercise that involves doing exercises with a physiotherapist in a heated swimming pool.  

We are running a study to try to better understand the impact that hydrotherapy might have on young people with DMD, and whether or not it offers any benefits to their physical and mental wellbeing. We will use the findings from the study to develop simple guides to advise on activities and exercise while in the water. 

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Lancashire Teaching Hospitals NHS Trust
Age
6-25
Mutation Specific
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

D-Brain

Defining outcome measures for behavioural and emotional problems in dystrophinopathies

Hub Summary

Research has shown that in a proportion of individuals with DMD and BMD, there might be some involvement of how the brain works. This can result in some individuals having a degree of learning difficulties, behavioural or psychological difficulties.

To investigate this, we are conducting a large cohort study to identify which part of the DMD gene is responsible for the development of these complications and help us further define and develop robust clinical assessments which will outline psychological profiles for DMD and BMD patients.

The study will involve two consecutive visits, which will include assessment of cognition (thinking and problem solving) and behaviour (inattention, anxiety, hyperactivity, etc.) . These two visits will be repeated after 6 months. For those interested there is also the possibility of participating in the MRI component of the study.

This study will cover your travel expenses and will provide you with detailed feedback on your son’s potential difficulties that can be used to receive educational support, to get a referral for local authorities or for your own personal use as it might give you some useful insights about your son’s behaviour.

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
UCL GOS Institute of Child Health
Age
7-17 years
Mutation Specific
Mutation specific therapies, A genetic mutation that decreases expression of Dp427 alone (assigned to BMD Group 1), of both Dp427 and Dp140 (assigned to BMD Group 2)
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Sarepta - MIS51ON

A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients WITH DUCHENNE MUSCULAR DYSTROPHY With Deletion Mutations Amenable to Exon 51 Skip

Hub Summary

This phase 3 study is designed to evaluate the safety and tolerability of two doses of eteplirsen. Part 1 (now closed for recruitment) will investigate two doses with Part 2 comparing the most effective dose from Part 1 with a 30mg/kg dose of eteplirsen. 

Study Number: NCT03992430

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
Sarepta Therapeutics
Age
4-13
Mutation Specific
Mutation specific therapies, must be amenable to exon 51 skipping
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Sarepta - EMBARK

A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Patients With Duchenne Muscular Dystrophy (EMBARK)

Hub Summary

This study will evaluate the safety and efficacy of gene transfer therapy in boys aged between 4 and 7 with DMD. It is a randomized, double-blind, placebo-controlled study. The participants who are randomized to the placebo arm will have an opportunity for treatment with gene transfer therapy at the beginning of the second year.

Study Number: NCT05096221

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
Sarepta Therapeutics, Inc.
Age
4 to 7 Years
Mutation Specific
Mutation specific therapies, A pathogenic frameshift mutation or premature stop codon contained between exons 18 and 79 (inclusive), with the exception of mutation fully contained within exon 45.
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

D3 Creatine

Changes in muscle mass using the D3-creatine dilution method and function in DMD

Hub Summary

This study will use a new, non-invasive method of measuring muscle mass in patients with Duchenne muscular dystrophy. It is jointly funded by Duchenne UK, Muscular Dystrophy Association and Parent Project Muscular Dystrophy.

Participants will attend 3 6-monthly study visits over the course of the study in line with regular clinic visits. At the visit, participants will drink a small amount of D3-creatine, which can be used to measure changes in the muscle by testing urine samples. There are no risks involved with drinking the solution - it has been tested in children and adults of all ages, as well as boys with DMD, with no adverse events being recorded so far.

During the visit, the participant will also undergo functional tests, including the NSAA (North Star Ambulatory Assessment), upper limb assessment and timed tests. This will help to demonstrate whether changes in muscle mass will be reflected in changes in function.

Study Number: IRAS - 297878

Learn More
Overall Trial Status
Fully recruited
UK Locations
Trial Sponsor
University of California, Berkeley
Age
5-25
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

WVE - N531

An Open-label Phase 1b/2a Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

Hub Summary

This is a phase 1b/2a looking at the safety of a new exon skipping investigational therapy, WVE-N531. Wave will also be looking at the pharmacokinetics (how the drug is absorbed and metabolised in the body) and pharmacodynamics (how the drug affects the body). 

Only patients who have a mutation amenable to exon 53 skipping are able to participate. 

Over the course of the trial, they will look to find the best dose of the investigational therapy, so patients will receive up to 4 dose levels, 4 weeks apart over the course of 16 weeks, and then receive an additional 3 doses every other week.  

Study Number: NCT04906460

Learn More
Overall Trial Status
Fully recruited
UK Locations
Trial Sponsor
Wave Life Sciences
Age
5-18
Mutation Specific
Mutation specific therapies, Exon 53
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Genethon - Natural History of Duchenne Muscular Dystrophy

A Prospective, Interventional, Baseline Study In Young Male Subjects Aged From 5 to 9 Years

Hub Summary

This natural history study is looking to collect data on the natural disease course in a cohort in young male subjects aged from 5 to 9 Years over a period of 6 to 36 months using disease appropriate evaluations.

Study Number: NCT03882827

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
Genethon
Age
5 to 9 Years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Pilot Study Comparing night time AFOs with CCDs in the management of ankle contractures

A pilot study to compare night time Ankle Foot Orthosis (AFOs) with Contracture Control Devices (CCDs) in the management of ankle contractures in ambulant boys with Duchenne Muscular Dystrophy (DMD)

Hub Summary

This pilot study aims to identify the sample size required to power a larger scale study to compare AFOs and CCDs in managing ankle range of movement and function in boys with Duchenne muscular dystrophy. It will also explore adherence and patient satisfaction for the two devices. 

This study is open to boys who are seen in Newcastle for clinical care and also in adjacent geographical areas to Newcastle who are willing to travel to Newcastle and who meet the inclusion criteria for the study. This includes those whose local physiotherapy providers support their inclusion in the study. Boys will need to be either night splint naive or have only introduced well-fitting night splints within the last 18 months.

Learn More
Overall Trial Status
Fully recruited
UK Locations
Trial Sponsor
Newcastle upon Tyne Hospitals NHS Foundation Trust
Age
4-10
Mutation Specific
All treatment types
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

FibroGen - LELANTOS

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Hub Summary

This phase 3 study is looking at the efficacy and safety of pamrevlumab versus a placebo, in combination with corticosteroids (deflazacourt or prednisone). It is only open to non-ambulant patients. There will be a placebo arm of the trial and 50% of the patients will be randomly allocated to each arm. Once all patients have completed the 52-week study, they may be eligible for rollover into an open-label extension (OLE) with pamrevlumab + corticosteroids. 

Pamrevlumab targets connective tissue growth factor (CFGF), which leads to muscle fibrosis. Stopping CTGF can improve muscle function. Data from the open-label Phase 2 clinical trial has shown that lung, heart and upper arm function was better preserved than usually expected in the normal progression of DMD. 

Study Number: NCT04371666

Learn More
Overall Trial Status
Trial terminated
UK Locations
Trial Sponsor
FibroGen
Age
12+
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Non-ambulant
DMD Hub logo

FibroGen - LELANTOS 2

A Phase 3 Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids, in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

Hub Summary

This phase 3 study is looking at the efficacy and safety of pamrevlumab versus a placebo, in combination with corticosteroids (deflazacourt or prednisone). The trial is open to patients who are able to complete the 6 Minute Walk test (6MWD) with a distance of at least 270m but no more than 450m on two occasions 3 months before starting on the trial, as well as being able to rise from the floor (TTSTAND) in less than 10 seconds at the screening visit. Patients must also be on a stable dose of corticosteroids for a minimum of 6 months.

There will be a placebo arm of the trial and 50% of the patients will be randomly allocated to each arm. Once all patients have completed the 52-week study, they may be eligible for rollover into an open-label extension (OLE) with pamrevlumab + corticosteroids. 

Pamrevlumab targets connective tissue growth factor (CFGF), which leads to muscle fibrosis. Stopping CTGF can improve muscle function. Data from the open-label Phase 2 clinical trial has shown that lung, heart and upper arm function was better preserved than usually expected in the normal progression of DMD.

 

 

Study Number: NCT04632940

Learn More
Overall Trial Status
Trial terminated
UK Locations
Trial Sponsor
FibroGen
Age
6-12
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

BIND Study

Brain INvolvement in Dystrophinopathies (BIND): Deep Functional Phenotyping of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy Patients (WP5) Part 1: a Multicentre Online Phenotyping and Neurobehavioural Data Collection Study

Hub Summary

This study is looking at the connection between the behavioural aspects of DMD and a patient's DMD gene mutation. Participants will be asked to complete an online questionnaire, which will take approximately 70mins and can be completed at multiple sittings. This is open to male DMD patients between 5 and 17yrs old. 

Study Number: NCT04583917

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
University College London
Age
5-17
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Interactive Virtual Reality System on Physiotherapy

Investigating the viability and acceptability of an Interactive Virtual Reality (IVR) System on physiotherapy rehabilitation in paediatric Duchenne Muscular Dystrophy (DMD) patients

Hub Summary

This study is looking at the use of Immersive Virtual Reality (IVR) to improve the uptake of physiotherapy amongst young people with DMD. The first phase will involve a design workshop to explore different scenarios on the IVR to mirror current DMD physiotherapy recommendations, with the second phase looking at testing of these scenarios by young people with DMD. The study is currently open to those patients currently being seen at Leeds Teaching Hospital and Sheffield Children's NHS Foundation Trust, and is being funded by The Children's Hospital Charity.

Study Number: Not on clinicaltrials.gov

Learn More
Overall Trial Status
Recruiting
UK Locations
Trial Sponsor
The Children's Hospital Charity (description by project team)
Age
5-10
Mutation Specific
All treatment types
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

NS Pharma - RACER53

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

Hub Summary

This is a placebo-controlled phase 3 study, designed to investigate the efficacy and safety of NS Pharma's exon skipping drug, Viltolarsen. It will be focusing on patients with mutations amenable to exon 53 skipping and will involve a weekly intravenous infusion over 48 weeks.

The dystrophin gene has 79 pieces called exons. These link together to form a code which instructs the body to make dystrophin. If there is a fault, as in DMD, the sequence is broken and the code cannot be read. Exon skipping drugs complete the sequence and leads to a shortened dystrophin being produced that still contains the important pieces of this molecule.

Study Number: NCT04060199

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
NS Pharma
Age
4-7
Mutation Specific
Mutation specific therapies, Exon 53
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Pfizer - CIFFREO

A Phase 3 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Hub Summary

This study is a phase 3 trial testing the safety and efficacy of Pfizer's gene therapy construct, PF-06939926. It is delivered using an adeno-associated virus, AAV, and carries a shortened version of the dystrophin gene (mini-dystrophin). The treatment will be given by an intravenous infusion. 

Two-thirds of the participants will receive the treatment. One-third will be randomly allocated to the placebo arm, but will be able to receive the treatment in the second year, so long as it remains safe to do so.

Please note that patients will need to be on daily steroids for 3 months before screening, to be eligible. They will also be able to be recruited to the trial up until their 8th birthday. For more information about the recruitment process for gene therapy trials, please click here

EU Clinical Trial Register number: 2019-002921-31

Study Number: NCT04281485

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
Pfizer Inc
Age
4-7
Mutation Specific
Non-mutation specific therapies , Some mutations are excluded (see exclusion criteria).
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Italfarmaco - Givinostat Extension

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Hub Summary

This study is an open label extension, looking at the long-term safety and tolerability of GIVINOSTAT in patients who have already taken part in and completed any of the previous studies. 

GIVINOSTAT is a drug that may help to promote muscle regeneration and reduce inflammation and fibrosis in DMD patients. 

This extension is expected to last until the drug receives the necessary approvals and is available on the market or the study needs to be stopped due to safety and/or efficacy reasons.

Study Number: NCT03373968

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
Italfarmaco
Age
7+
Mutation Specific
All treatment types
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Sarepta - MOMENTUM

A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Hub Summary

This phase 2 study is designed to determine the maximum dose for Sarepta Therapeutics Exon 51 skipping therapy, as well as its safety and tolerability.

There will be two arms to the study - in Part A, patients will receive 1 of 5 doses of SRP-5051 monthly by intravenous infusion. Once the maximum dose has be has been determined, all patients will then roll over into Part B and will receive the maximum dose by intravenous infusion for 24 weeks. In Part B, an additional 15 patients will also be enrolled at the beginning of the study. 

Part A recruitment has now been completed and Part B will be beginning soon, involving the original patients from Part A as well as some additional patients. 

The UK sites have not yet been finalised, we will provide an update once we have these details.

Study Number: NCT04004065

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
Sarepta Therapeutics
Age
7-21 years old
Mutation Specific
Mutation specific therapies, must be amenable to exon 51 skipping
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Testosterone in DMD follow up study

Long term observational extension study of gonadal function after pubertal induction in Duchenne Muscular Dystrophy

Hub Summary

This study will be investigating the effects of testosterone being used over the course of 2 years to bring on puberty in boys with DMD. Puberty is often delayed in boys with DMD, and is a side effect of taking steroids, which are part of the Standards of Care. This study will be looking not only at the physical effects of taking testosterone, but also the emotional and psychological effects. 

Please note this trial is only open to boys who took part in the original observational study (NCT02571205) and is by invitation only. 

Study Number: Not on ClinicalTrials.gov

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Newcastle upon Tyne Hospitals NHS Foundation Trust
Age
12-17
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Sarepta Extension Study for Casimersen or Golodirsen

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Hub Summary

This is an open-label, non-randomized extension trial for patients who have already taken part in the trials testing the drugs, casimersen or golodirsen, to evaluate the effects of their long term use. 

This trial focuses on patients with Exon 45 and Exon 53 mutations, and will involve weekly intravenous infusions of 30mg/kg for up to 2 years. 

Study Number: NCT03532542

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Sarepta Therapeutics
Age
7-23
Mutation Specific
Mutation specific therapies, Exon 45 (Casimersen) and Exon 53 (Golodirsen)
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

MCID DMD

Minimal Clinically Important Difference (MCID) in Duchenne Muscular Dystrophy (DMD) tests

Hub Summary

This study is looking at whether we can quantify the smallest change in two outcome measures that is meaningful for families, patients and clinicians. Participation in this study includes just a one-off questionnaire which takes around 30-45 minutes to complete. 

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health
Age
7 to 18 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Sarepta- ESSENCE

Study of SRP-4045 and SRP-4053 in DMD Patients

Hub Summary

This study is a stage 3 trial of Sarepta's exon 45 and exon 53 skipping drugs. Exon skipping drugs use a small piece of genetic material to skip over the part of the dystrophin gene with a mutation. The part of the dystrophin gene with a mutation varies between patients. Therefore, exon skipping trials are mutation specific. This trial requires you to be amenable to the skipping of exon 45 or 53.

The main objective of this study is to determine the efficacy of the drugs compared to a placebo in DMD patients.

Study Number: NCT02500381

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
Sarepta Therapeutics, Inc.
Age
7-13
Mutation Specific
Mutation specific therapies, Must be amenable to exon 45 or 53 skipping
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Wave Life Sciences Exon 51

A Multicentre, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy

Hub Summary

This phase 1 study is designed to determine the safety and tolerability of Wave Life Science’s Exon 51 skipping therapy.

Study Number: NCT03508947

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
Wave Life Sciences
Age
5 to 18 years
Mutation Specific
Mutation specific therapies, must be amenable to exon 51 skipping
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Brain study

Brain imaging and Cognition in patients with DMD

Hub Summary

This 2-year natural history study is designed to study the progression of pathological changes in the brain associated with the absence of dystrophin. The study will focus on cognitive impairment as well as looking at the relationship between the outcome measures and behavioural functioning.

Study Number: NOT ON clinicaltrials.gov

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Newcastle-upon-Tyne Hospitals NHS trust
Age
8 and over
Mutation Specific
All treatment types
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Vamorolone Phase 2b (VISION-DMD)

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Hub Summary

This Phase 2b study is designed to evaluate the efficacy, safety pharmacodynamics and pharmacokinetics of vamorolone in comparison to corticosteroids and placebo treatments over a 24 week period. The study will also evaluate the persistence of the effect of vamorolone over a period of 48 weeks. 

The study is designed to compare 2 different doses of Vamorolone to a standard dose of corticosteroids (prednisone at 0.75 mg/kg/day) and to a placebo. Across all sites, this trial will be recruiting a total of 120 ambulant DMD patients ages 4 to <7 years. 

Study Number: NCT03439670

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
ReveraGen BioPharma
Age
4 to 7 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Tamoxifen (TAMDMD)

Tamoxifen in Duchenne Muscular Dystrophy

Hub Summary

This placebo control, 48-week clinical trial will look at the treatment with Tamoxifen for both ambulant and non-ambulant patients with DMD. Tamoxifen has been used to treat breast cancer since the 1980s and is also used for hormonal disorders in pre-pubescent boys. Preliminary data in the DMD mouse model demonstrated that Tamoxifen reduced fibrosis, increased the thickness of muscle fibres, and resulted in a delay in disease progression.

Study Number: NCT03354039

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
University Children's Hospital Basel
Age
78 months to 16 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Disease translation in DMD: Neuromuscular rare disease translational research in patients with DMD.

Disease translation in DMD

Hub Summary

This study is designed to study a number of genes considered to be modifiers for DMD. This translational research will identify and obtain DNA samples and clinical information from 400 cases with DMD. This data will then be grouped into clinically and genetically defined groups. The DNA of the participants will be analysed and correlated to motor performance, age at loss of ambulation, severity of respiratory failure and severity of cardiac impairment. 

Study Number: Not on clinicaltrials.gov

Learn More
Overall Trial Status
Recruiting
Trial Sponsor
Great Ormond Street Hospital NHS Foundation Trust
Age
>5 years old
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
DMD Hub logo

Vamorolone Phase II Extension

Long-term extension Study to Assess Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)

Hub Summary

This extension study is designed to assess the safety of using vamorolone long term in children with DMD. The study will also compare muscle function to boys with DMD in other studies who did not take steroids as well as comparing weight gain with boys taking vamorolone and boys taking traditional steroids (prednisone).

Vamorolone is a steroid alternative which is designed to be an alternative to corticosteroids with reduced side effects.

Study Number: NCT03038399

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
ReveraGen BioPharma, Inc.
Age
4-7
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Testosterone for DMD

Testosterone therapy for Pubertal delay in DMD

Hub Summary

This observational study is looking at the outcomes of testosterone treatment in boys with DMD. The study is following the progression of adolescent males with DMD and delayed puberty. These patients are treated with testosterone to induce puberty. The participants are treated with the standard regiment of testosterone and this study is collecting data to review the effectiveness and tolerability of the current treatment regimen.

The researchers will use the results to explore what effect testosterone treatment has on pubertal development, growth, muscle strength and function, bone mineral density and body composition. The study also aims to define and understand side effects testosterone treatment may have.

Study Number: NCT02571205

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Newcastle-upon-Tyne Hospitals NHS Trust
Age
12-17
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Italfarmaco- Givinostat (EPIDYS)

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients with Duchenne Muscular Dystrophy (EPIDYS)

Hub Summary

This study will compare the change in stair climb test and other functional tests in patients taking givinostat and patients taking a placebo. Givinostat has potential anti-inflammatory, antifibrotic and proregenerative effects.

Please note this protocol was amended early 2019.

Study Number: NCT02851797

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
Italfarmaco
Age
6-17
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Outcome measures

Outcome measures in Duchenne Muscular Dystrophy: A natural history study

Hub Summary

With so many new therapies emerging for DMD, it is important we understand the natural history of the disease. This natural history study will assess the natural history of DMD sing a selection of assessment tools. The aim is to obtain natural history data to capture disease progression linking the ambulant and non-ambulant phases of DMD. This study will also provide an insight into the relationship between different assessment tools which are used in the clinic. 

Study Number: NCT02780492

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
University College, London
Age
5-18
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

KINEDMD

KINEDMD

Hub Summary

This study is for proof of concept, designed to use artificial intelligence to identify kinematic biomarkers (fingerprints of movement) of DMD progression. This could speed up drug development for new therapies and repurposed drugs, in order to deliver treatments to children as fast as possible.

Once fingerprints of movement specific for DMD boys are identified, the results will be published and made available to the whole community. This pilot study also wishes to lay the foundation for future validation of these novel biomarkers. This is an opportunity to take part in innovative natural history research that could improve clinical trial design for future trials.

Duchenne Research Fund is the funding body for this study. 

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Imperial College London
Age
6 to 17 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

RIM4DMD

Rimeporide in patients with Duchenne muscular dystrophy

Hub Summary

Patients with DMD have imbalanced levels of calcium and sodium in their muscle cells, this is thought to play a key part in the damage which occurs to muscles. This study is evaluating the safety and tolerability of rimeporide. Rimeporide is a drug which works by inhibiting the movement of sodium and calcium from muscle cells. Inhibition of this mechanism has been proven to be efficient in preventing inflammation and fibrosis (muscle damage) in animal models. In addition to the preventative effect on muscle damage, rimeporide was also shown to be cardioprotective. 

This investigational treatment could have no restriction on age and is not mutation specific, meaning it could treat all patients with DMD. This phase 1b study will examine Rimeporide in patients aged 6 to 14 years.

Study Number: NCT02710591

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
EspeRare Foundation
Age
6-14
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

PTC Ataluren Phase 3

Phase 3 Extension study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy

Hub Summary

DMD is caused by a mutation in the gene which produces dystrophin. Dystrophin functions to maintain muscle structure and function. The loss of dystrophin in DMD leads to muscle weakness and loss of ambulation. A nonsense mutation is a specific type of mutation which is the cause of DMD in 10-15% of patients.

Ataluren is a drug designed to make the body's machinery less sensitive to nonsense mutations. This phase 3 trial is designed to assess the long-term safety of Ataluren in boys with nonsense dystrophinopathies. The study will also assess changes in clinical measures such as muscle function and pulmonary function.

Study Number: NCT02090959

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
PTC Therapeutics
Age
7-18
Mutation Specific
Mutation specific therapies, Nonsense mutations only
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

FOR-DMD

Finding the optimum regimen for Duchenne Muscular Dystrophy

Hub Summary

FOR-DMD study is designed to compare three different ways of giving corticosterioids to boys with DMD. The aim of this study is to see which method increases muscle strength the most and which produces the fewest side effects. The results of this study should provide patients and caregivers clearer information and guidelines about the best ways to take corticosteroids. The study will look at the following administration of corticosteroids:

  • Prednisone 0.75mg/kg/day
  • Prednisone 0.75mg/kg/day with 10 days on/10 days off treatment
  • Deflazacort 0.9mg/kg/day

Study Number: NCT01603407

Learn More
Overall Trial Status
Trial complete
Trial Sponsor
University of Rochester
Age
4-7
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Patient Registry Translarna (Ataluren)

Long-term observational study of Translarna safety and effectiveness in usual care

Hub Summary

This phase 4 clinical study is designed to assess the safety of Translarna, also known at Ataluren. This study will follow patients who are receiving Translarna as part of their usual care for 5 years. At the patients usual visits, data will be collected to determine the safety and effectiveness of Translarna. 

Study Number: NCT02369731

Learn More
Overall Trial Status
Fully recruited
Trial Sponsor
PTC Therapeutics
Age
Child, adolescent and adult
Mutation Specific
Mutation specific therapies, Nonsense mutation
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Sarepta 53

Phase I/II Study of SRP-4053 in DMD Patients

Hub Summary

This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics of Sarepta's exon skipping drug SRP-4053. SRP-4053 is designed to treat patients with DMD with deletions amenable to exon 53 skipping.

Study Number: NCT02310906

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Sarepta Therapeutics, Inc.
Age
6-15
Mutation Specific
Mutation specific therapies, Amenable to exon 53 skipping
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Ataluren long-term

Study of Ataluren for previously treated patients with nmDBMD in Europe, Israel, Australia and Canada

Hub Summary

DMD is caused by a mutation in the gene which produces dystrophin. Dystrophin functions to maintain muscle structure and function. The loss of dystrophin in DMD leads to muscle weakness and loss of ambulation. A nonsense mutation is a specific type of mutation which is the cause of DMD in 10-15% of patients.

Ataluren is a drug designed to make the body's machinery less sensitive to nonsense mutations. This phase 3 trial is designed to assess the long-term safety and tolerability of Ataluren.

Study Number: NCT01557400

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
PTC Therapeutics
Age
All
Mutation Specific
Mutation specific therapies, Nonsense mutations only
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Non-ambulant
DMD Hub logo

PreU7-53

Observational study of patients with DMD theoretically treatable with exon skipping 53

Hub Summary

PreU7-53 is an observational cohort study. This natural history study is designed to monitor upper limb muscle impairment in patients potentially treatable with AAV-mediated exon skipping.

Study Number: NCT01385917

Learn More
Overall Trial Status
Trial complete
UK Locations
Trial Sponsor
Genethon
Age
12-20
Mutation Specific
Mutation specific therapies, Amenable to treatments with Exon 53 skipping
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Non-ambulant
DMD Hub logo

DYSTANCE 51 [TERMINATED]

A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Study of Suvodirsen (WVE-210201) With Open Label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Hub Summary

Please note that Wave have stopped the development of this drug after the Phase 1 Open-label extension failed to meet its primary endpoint. 

DYSTANCE 51 is a phase 2/3 clinical trial designed to evaluate the efficacy and safety of WVE-210201 (suvodirsen) in ambulant boys with DMD mutations amenable to exon 51 skipping.

DYSTANCE 51 is comprised of two phases, a placebo-controlled phase and an open-label phase. In the placebo-controlled phase, patients will be randomized to receive suvodirsen 3 mg/kg, suvodirsen 4.5 mg/kg or placebo for 48 weeks. Dystrophin protein levels and functional outcomes will be assessed for each patient throughout the initial 48-week treatment period.

Each participant will have two biopsies in total, one at baseline, and one at either week 12, 22, or 46.

Following completion of the placebo-controlled phase of the study, patients will enter the open-label phase to receive ongoing treatment with suvodirsen. There will be no placebo or biopsies in the open label phase. However, functional assessments will continue.

Study Number: NCT03907072

Learn More
Overall Trial Status
Trial terminated
Trial Sponsor
Wave Life Sciences Ltd
Age
5-12 years old
Mutation Specific
Mutation specific therapies, Amenable to exon 51 skipping
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Catabasis - Galaxy DMD [TERMINATED]

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

Hub Summary

This is an open label extension trial for patients who completed the POLARIS-DMD trial, and their siblings who meet the inclusion criteria between the ages of 4-12yrs (up to their 13th birthday). 

This trial is looking at the safety, tolerability and durability of taking edasalonexent over a long period of time. Edasalonexent has been shown to delay the progression of DMD and could provide an alternative to steroids. It is in tablet form and taken orally (by mouth) three times a day. 

Study Number: NCT03917719

Learn More
Overall Trial Status
Trial terminated
Trial Sponsor
Catabasis Pharmaceuticals
Age
4-12
Mutation Specific
All treatment types
Muscle Biopsy
Ambulation
Ambulant
DMD Hub logo

Phase 3 PolarisDMD Trial [TERMINATED]

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (PolarisDMD)

Hub Summary

 PolarisDMD is a global, placebo controlled, Phase 3 trial for edasolonexent (CAT-1004). Edasalonexent is an NF-kB inhibitor, which could provide an alternative to steroids. Edasalonexent has been shown to preserve muscle function and substantially slow Duchenne disease progression in the MoveDMD trial.

This trial will evaluate the efficacy and safety of edasolonexent in patients with DMD, and is intended to support an application for commercial licencing of edasolonexent.

To receive up-to-date information about this trial, please sign up to the Catabasis newsletter

Study Number: NCT03703882

Learn More
Overall Trial Status
Trial terminated
Trial Sponsor
Catabasis Pharmaceuticals
Age
4-7 years
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Roche- RO7239361 [TERMINATED]

Clinical trial to Evaluate the Efficacy, Safety and Tolerability of RO7239361 in Ambulatory Boys with Duchenne muscular dystrophy

Hub Summary

Please note the development of this drug was stopped after this trial failed to reach its objectives.

This placebo-controlled study is designed to assess the efficacy, safety and tolerability of two different doses of RO7239361 in ambulatory males with DMD. RO7239361 is a subcutaneously delivered treatment which inhibits myostatin.

Myostatin is a protein in the body which inhibits muscle growth and it is required to stop muscles from growing too large. Myostatin production increases naturally with age. It is thought that inhibiting myostatin function could lead to increased muscle size and strength in patients with DMD.

Study Number: NCT03039686

Learn More
Overall Trial Status
Trial terminated
UK Locations
Trial Sponsor
Hoffmann-La Roche
Age
6-11
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Santhera SIDEROS Open Label Extension [TERMINATED]

Phase III Study with Idebenone in Patients with Duchenne Muscular Dystrophy

Hub Summary

This study is a stage 3 trial of Sanethera's Idebenone drug and it's long term effects in delaying the loss of lung function in patients with DMD, receiving glucocorticoid steroids. This trial is only open to those patients who were part of the SIDEROS trial and are currently taking steroids. 

Study Number: NCT03603288

Learn More
Overall Trial Status
Trial terminated
Trial Sponsor
Santhera Pharmaceuticals
Age
11 +
Mutation Specific
All treatment types
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Domagrozumab phase 2 [TERMINATED]

Please note that Pfizer stopped the development of this drug after the Phase 2 failed to meet its primary endpoint. 

Hub Summary

This phase 2 trial is designed to evaluate the safety and efficacy of Domagrozumaub, a myostatin inhibitor. Myostatin is a protein in the body which inhibits muscle growth and it is required to stop muscles from growing too large. It is thought that inhibiting myostatin may help preserve or improve muscle function in patients with DMD. 

Study Number: NCT02310763

Learn More
Overall Trial Status
Trial terminated
UK Locations
Trial Sponsor
Pfizer
Age
6-16
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant
DMD Hub logo

Santhera (SIDEROS) [TERMINATED]

A Phase III Double-blind Study with Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) taking Glucocorticoid Steroids

Hub Summary

The SIDEROS trial is designed to determine the effect of idebenone at delaying the loss of lung function in patients with DMD, receiving glucocorticoid steroids. This is a placebo-controlled trial.

Study Number: NCT02814019

Learn More
Overall Trial Status
Trial terminated
Trial Sponsor
Santhera Pharmaceuticals
Age
10 years +
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Ambulant and non-ambulant
DMD Hub logo

Domagrozumab extension [TERMINATED]

Please note that Pfizer stopped the development of this drug after the Phase 2 failed to meet its primary endpoint.

Hub Summary

This study is designed to evaluate the safety and efficacy of Domagrozumaub, a myostatin inhibitor. Myostatin is a protein in the body which inhibits muscle growth and it is required to stop muscles from growing too large. It it thought that inhibiting myostatin may help preserve or improve muscle function in patients with DMD. 

This is an open-label extension study of the Phase 2 study of Domagrozumaub - subjects are only eligible for this study if they were enrolled into and completed the phase 2 study. 

Study Number: NCT02907619

Learn More
Overall Trial Status
Trial terminated
UK Locations
Trial Sponsor
Pfizer
Age
6 - 18
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
No Muscle Biopsy Required
Ambulation
Non-ambulant
DMD Hub logo

Summit- Ezutromid (PhaseOut DMD) [TERMINATED]

Please note the development of this drug was stopped after this trial failed to reach its objectives.

Hub Summary

This phase 2 clinical trial is designed to assess the activity and safety of Utrophin modulation in patients with DMD with SMT C1100 (Ezutromid). Ezutromid is an orally administered small molecule utrophin modulator.

Utrophin is a bodily protein which is structurally and functionally similar to dystrophin. Utrophin is naturally produced in the early stages of muscle development but is turned off as muscle fibres mature and dystrophin increases to perform the same role. Utrophin modulation aims to maintain the production of utrophin to compensate for the absence of dystrophin in patients with DMD.

This 1 year study has an optional extension phase. 

Study Number: NCT02858362

Learn More
Overall Trial Status
Trial terminated
UK Locations
Trial Sponsor
Summit Therapeutics
Age
5-10
Mutation Specific
Non-mutation specific therapies
Muscle Biopsy
Muscle Biopsy Required
Ambulation
Ambulant

We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here